Anti-Diabetic Medications Do Not Influence Risk of Lung Cancer in Patients with Diabetes Mellitus: a Systematic Review and Meta-analysis |
Nie, Shu-Ping
(Clinical Epidemiology Unit, Qilu Hospital of Shandong University)
Chen, Hui (Clinical Epidemiology Unit, Qilu Hospital of Shandong University) Zhuang, Mao-Qiang (Shandong Center for Disease Control and Prevention) Lu, Ming (Clinical Epidemiology Unit, Qilu Hospital of Shandong University) |
1 | Ruiter R, Visser LE, van Herk-Sukel MP, et al (2012). Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: Results from a large populationbased follow-up study. Diabetes Care, 35, 119-24. DOI |
2 | Smiechowski BB, Azoulay L, Yin H, Pollak MN, Suissa S (2013). The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care, 36, 124-9. DOI |
3 | Soranna D, Scotti L, Zambon A, et al (2012). Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: A meta-analysis. Oncologist, 17, 813-22. DOI |
4 | Spitz MR, Hong WK, Amos CI, et al (2007). A risk model for prediction of lung cancer. J Natl Cancer Inst, 99, 715-26. DOI ScienceOn |
5 | Staimez LR, Weber MB, Narayan KM, Oza-Frank R (2013). A systematic review of overweight, obesity, and type 2 diabetes among Asian American subgroups. Curr Diabetes Rev, 9, 312-31. DOI |
6 | Tammemagi CM, Pinsky PF, Caporaso NE, et al (2011). Lung cancer risk prediction: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst, 103, 1058-68. DOI |
7 | Tobias A (1999). Assessing the influence of a single study in the meta-analysis estimate.15-7. |
8 | Tong GX, Cheng J, Chai J, et al (2014). Association between gestational diabetes mellitus and subsequent risk of cancer: A systematic review of epidemiological studies. Asian Pac J Cancer Prev, 15, 4265-9. 과학기술학회마을 DOI |
9 | Tyczynski JE, Bray F, Parkin DM (2003). Lung cancer in Europe in 2000: Epidemiology, prevention, and early detection. Lancet Oncol, 4, 45-55. DOI |
10 | van Staa TP, Patel D, Gallagher AM, de Bruin ML (2012). Glucose-lowering agents and the patterns of risk for cancer: A study with the General Practice Research Database and secondary care data. Diabetologia, 55, 654-65. DOI |
11 | Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R (2009). Diabetes and cancer. Endocr Relat Cancer, 16, 1103-23. DOI ScienceOn |
12 | Wang SY, Chuang CS, Muo CH, et al (2013). Metformin and the incidence of cancer in patients with diabetes: A nested case-control study. Diabetes Care, 36, e155-6. |
13 | Wells GA, Shea B, O'Connell D, et al (2013). The Newcastle- Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses.http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed April 3, 2013. |
14 | Wu CY, Hu HY, Pu CY, Huang N, Shen HC, Li CP, Chou YJ (2011). Pulmonary tuberculosis increases the risk of lung cancer: A population-based cohort study. Cancer, 117, 618-24. DOI |
15 | Yang X, Xu C, Sun Y, Han R (2013). Diabetes mellitus increases the risk of bladder cancer: An updated meta-analysis. Asian Pac J Cancer Prev, 14, 2583-9. 과학기술학회마을 DOI ScienceOn |
16 | Zabetian A, Keli HM, Echouffo-Tcheugui JB, Narayan KM, Ali MK (2013). Diabetes in the middle east and north africa. Diabetes Res Clin Pract, 101, 106-22. DOI |
17 | Ding J, Tang J, Chen X, et al (2013). Expression characteristics of proteins of the insulin-like growth factor axis in non-small cell lung cancer patients with preexisting type 2 diabetes mellitus. Asian Pac J Cancer Prev, 14, 5675-80. 과학기술학회마을 DOI ScienceOn |
18 | Egger M, Davey SG, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. DOI ScienceOn |
19 | Ehrlich SF, Quesenberry CJ, Van Den Eeden SK, Shan J, Ferrara A (2010). Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care, 33, 55-60. DOI |
20 | Franciosi M, Lucisano G, Lapice E, et al (2013). Metformin therapy and risk of cancer in patients with type 2 diabetes: Systematic review. PLoS One, 8, 71583. DOI |
21 | Gallagher EJ, LeRoith D (2011). Diabetes, cancer, and metformin: Connections of metabolism and cell proliferation. Ann N Y Acad Sci, 1243, 54-68. DOI ScienceOn |
22 | Gao Y, Goldstein AM, Consonni D, etal (2009). Family history of cancer and nonmalignant lung d iseases as risk factors for lung cancer. Int J Cancer, 125, 146-52. DOI |
23 | Govindarajan R, Ratnasinghe L, Simmons DL, et al (2007). Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol, 25, 1476-81. DOI ScienceOn |
24 | Gu Y, Wang C, Zheng Y, et al (2013). Cancer incidence and mortality in patients with type 2 diabetes treated with human insulin: A cohort study in Shanghai. PLoS One, 8, 53411. DOI |
25 | Hall GC, Roberts CM, Boulis M, Mo J, MacRae KD (2005). Diabetes and the risk of lung cancer. Diabetes Care, 28, 590-4. DOI |
26 | Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. DOI ScienceOn |
27 | Hsieh MC, Lee TC, Cheng SM, et al (2012). The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res, 2012, 413782. |
28 | Jalving M, Gietema JA, Lefrandt JD, et al (2010). Metformin: Taking away the candy for cancer? Eur J Cancer, 46, 2369-80. DOI |
29 | Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. DOI |
30 | Johnson JA, Yasui Y (2010). Glucose-lowering therapies and cancer risk: The trials and tribulations of trials and observations. Diabetologia, 53, 1823-6. DOI |
31 | Kao CH, Sun LM, Chen PC, et al (2013). A population-based cohort study in Taiwan--use of insulin sensitizers can decrease cancer risk in diabetic patients? Ann Oncol, 24, 523-30. DOI |
32 | Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA (2011). Risk of cancer in a large cohort of U.S. Veterans with diabetes. Int J Cancer, 128, 635-43. DOI ScienceOn |
33 | Awoniyi O, Rehman R, Dagogo-Jack S (2013). Hypoglycemia in patients with type 1 diabetes: Epidemiology, pathogenesis, and prevention. Curr Diab Rep, 13, 669-78. DOI |
34 | Bach PB, Kattan MW, Thornquist MD, et al (2003). Variations in lung cancer risk among smokers. J Natl Cancer Inst, 95, 470-8. DOI ScienceOn |
35 | Bodmer M (2012). Metformin does not alter the risk of lung cancer: A case-control analysis. Lung Cancer, 78, 133-7. DOI |
36 | Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006). Increased Cancer-Related Mortality for Patients with Type 2 Diabetes Who Use Sulfonylureas or Insulin. Diabetes Care, 29, 254-8. DOI ScienceOn |
37 | Bruske-Hohlfeld I (2009). Environmental and occupational risk factors for lung cancer. Methods Mol Biol, 472, 3-23. DOI |
38 | Cassidy A, Myles JP, van Tongeren M, et al (2008). The LLP risk model: An individual risk prediction model for lung cancer. Br J Cancer, 98, 270-6. DOI |
39 | Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM (2012). Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab, 97, E1170-5. DOI |
40 | Decensi A, Puntoni M, Goodwin P, et al (2010). Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev Res (Phila), 3, 1451-61. DOI ScienceOn |
41 | Lai SW, Liao KF, Chen PC, et al (2012). Antidiabetes drugs correlate with decreased risk of lung cancer: A populationbased observation in Taiwan. Clin Lung Cancer, 13, 143-8. DOI |
42 | Lam WK, White NW, Chan-Yeung MM (2004). Lung cancer epidemiology and risk factors in Asia and Africa. Int J Tuberc Lung Dis, 8, 1045-57. |
43 | Leone A, Di Gennaro E, Bruzzese F, Avallone A, Budillon A (2014). New perspective for an old antidiabetic drug: Metformin as anticancer agent. Cancer Treat Res, 159, 355-76. DOI |
44 | Libby G, Donnelly LA, Donnan PT, et al (2009). New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care, 32, 1620-5. DOI ScienceOn |
45 | Long YC, Zierath JR (2006). AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest, 116, 1776-83. DOI ScienceOn |
46 | Luo J, Chlebowski R, Wactawski-Wende J, et al (2012). Diabetes and lung cancer among postmenopausal women. Diabetes Care, 35, 1485-91. DOI |
47 | Mazzone PJ, Rai H, Beukemann M, Xu M, Jain A, Sasidhar M (2012). The effect of metformin and thiazolidinedione use on lung cancer in diabetics. Bmc Cancer, 12, 410. DOI |
48 | Mulshine JL, Sullivan DC (2005). Clinical practice. Lung cancer screening. N Engl J Med, 352, 2714-20. DOI ScienceOn |
49 | Noto H, Goto A, Tsujimoto T, Noda M (2012). Cancer risk in diabetic patients treated with metformin: A systematic review and meta-analysis. PLoS One, 7, 33411. DOI |
50 | Ogunleye AA, Ogston SA, Morris AD, Evans JM (2009). A cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer, 101, 1199-201. DOI |
51 | Okumura T (2010). Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs. J Gastroenterol, 45, 1097-102. DOI |
52 | Rousseau M, Parent M, Pollak MN, Siemiatycki J (2006). Diabetes mellitus and cancer risk in a population-based case-controlstudy among men from Montreal, Canada. Int J Cancer, 118, 2105-9. DOI ScienceOn |
53 | Ruano-Ravina A, Figureueiras A, Barros-Dios JM (2003). Lung cancer and related risk factors: An update of the literature. Public Health, 117, 149-56. DOI |
54 | Ferrara A, Lewis JD, Quesenberry CJ, et al (2011). Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care, 34, 923-9. DOI ScienceOn |